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 Lactose Intolerance: New Insights due to 
Blinded Testing? 
 Benjamin Misselwitz  
 Division of Gastroenterology and Hepatology, University Hospital Zurich,  Zurich , Switzerland
 
 Lactose intolerance (LI) refers to the development of 
symptoms after ingestion of lactose. LI can explain symp-
toms for some patients with diarrhea and abdominal 
pain. Learning from experience, patients will decrease 
milk and calcium consumption, possibly resulting in an 
increased risk for osteoporosis and bone fractures  [4] .
 LI is not synonymous with and should not be confused 
with LM. Symptom development depends on the amount 
of lactose ingested, the colonic microbiota, individual 
sensitivity and subjective expectations  [5] . Patient history 
can therefore be misleading: when tested in a blinded set-
ting, individuals with self-diagnosed severe LI were able 
to ingest up to 12 g of lactose (corresponding to 250 ml of 
milk) and some of these individuals did not even have the 
LM phenotype  [6] .
 A 2010 NIH conference therefore proposed a new def-
inition of LI  [7] . LI now refers to  the development of symp-
toms after blinded lactose challenge in an individual with 
LM . Strictly speaking, testing of LI would therefore be a 
two-step procedure. First, the LM phenotype should be 
established. For this task, many tools including genetic 
analysis, the H 2 -breath test and measurements of lactase 
expression in duodenal biopsies are available. For the as-
sessment of LI, blinded testing would be required, but so 
far no validated clinical tools are available. Therefore, LI 
according to the NIH definition cannot be diagnosed in 
today’s clinical practice.
 In the current issue of  Digestion , Latorre et al.  [8] 
report the first study where testing for LI has been 
performed according to the NIH definition. 121 healthy 
 All human newborns and basically all newborn mam-
mals express the enzyme lactase in the small intestine. 
This enables the digestion of lactose and the ability to 
thrive on milk as the only nutrient. However, later in life 
lactase expression is downregulated in animals and most 
humans, a process which possibly facilitates weaning. Af-
ter lactase downregulation, lactose will reach the colonic 
microbiota, resulting in the production of short-chain 
fatty acids, hydrogen and methane, which can potentially 
cause gastrointestinal symptoms.
 5,000–10,000 years BC in central Europe, a mutation 
within the promoter of the lactase gene occurred, result-
ing in the persistence of lactase expression also in adults 
 [1] . This LCT-13910C>T mutation has been of tremen-
dous evolutionary advantage, increasing evolutionary fit-
ness by up to 19% in each generation  [2] . Lactase persis-
tence enabled our farming ancestors to ingest milk in 
large quantities, providing a clean source of liquid, calo-
ries and vitamin D. Due to these benefits, the mutation in 
the lactase promoter spread and in central and northern 
Europe as well as in North America lactase persistence 
(resulting in lactose digestion) is now the most frequent 
phenotype. However, in most areas of the world, includ-
ing most parts of Asia and Africa, lactase nonpersistence 
and lactose maldigestion (LM) remain the most frequent 
conditions. For European and North American physi-
cians, it is thus important to realize that lactase nonper-
sistence and LM are not a disease but a normal human 
phenotype  [3] .
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Chilean students without gastrointestinal symptoms in-
gested 25 g of lactose or sucrose in a double-blinded set-
ting, and H 2 -concentration in expiratory air and symp-
toms were monitored. Among the study subjects, 69 out 
of 121 individuals (57%) had genetic lactase nonpersis-
tence and 60 of those 69 (87%) had a positive H 2 -breath 
test. The correlation of the genetic test and the H 2 -breath 
test is therefore not perfect. Reasons for discrepancies in-
clude a colon flora unable to produce hydrogen (‘non-H 2 -
producers’), secondary lactase deficiency and complex 
genetic mechanisms determining lactase expression 
which are not entirely understood yet.
 Importantly, 56% of all the subjects with proven lactose 
malabsorption in the H 2 -breath test also had LI. The thresh-
old chosen for scoring ‘positive’ symptoms in this study was 
relatively low (6-point difference relative to placebo on a 
50-point scale) and a more stringent threshold might have 
decreased the percentage of individuals with true LI ac-
cording to the NIH definition. In any case, a test distin-
guishing approximately 50% of individuals potentially ben-
efitting from further treatment (lactose-reduced diet or lac-
tase enzyme treatment) could be clinically very useful.
 Should blinded testing now be universally introduced 
into clinical practice? Not necessarily. These results just 
reflect the situation in a population of healthy young stu-
dents (mean age 21 years). In contrast, the patient popu-
lation referred to LI testing likely has a higher prevalence 
of irritable bowel syndrome (IBS), self-diagnosis of LI 
and/or psychiatric comorbidity.
 Furthermore, future studies need to address whether 
blinded testing can actually improve patient management. 
It would be interesting to learn whether blinded testing 
would improve calcium intake and bowel symptoms sev-
eral months after lactose tolerance testing. Blinded multi-
ple-dose testing to determine the maximum tolerated lac-
tose dosage  [9] might further improve dietary manage-
ment. Therefore, assessment of symptoms does not need 
to be done simultaneously to an H 2 -breath test, but could 
also be done at patients’ homes in an inexpensive manner.
 Finally, it seems appropriate to regard LI not as an iso-
lated condition, but as a manifestation of functional bow-
el disorders including IBS. In fact, in Chinese probands 
with a prevalence of LM approximating 100%, symptoms 
after lactose challenge occurred at a much higher fre-
quency in individuals fulfilling diagnostic criteria of IBS 
compared to controls  [9] . However, lactose is not the only 
nutrient fermented by the colonic microbiota after mal-
digestion in the small intestine, and a group of nutrients 
with a similar profile (FODMAPs, i.e. fermentable oligo-, 
di- and monosaccharides and polyols) has been identi-
fied. A diet low in FODMAPs has recently been shown to 
improve symptoms in patients with IBS  [10] . Lactose 
could be the leading FODMAP in IBS patients with LM 
and a lactose-rich diet. For other IBS patients, other nu-
trients could be causing symptoms. Therefore, rational 
dietary management of IBS patients might first include a 
lactulose test meal in a controlled and blinded setting  [11] 
(lactulose will be fermented by the colon microbiota and 
thus act as a FODMAP in all individuals). Only individu-
als with symptoms should be referred for more special-
ized testing including LM and blinded LI testing.
 Taken together, blinded testing of nutrients is a new 
concept in functional diagnostics in gastroenterology 
with the potential to improve the management of patients 
with nutrition-dependent abdominal symptoms. How-
ever, further tests will be needed to determine the applica-
tion of LI testing which will benefit our patients best.
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